Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.

Kim GB, Hege K, Riley JL.

Front Immunol. 2019 Sep 27;10:2310. doi: 10.3389/fimmu.2019.02310. eCollection 2019. Review.

PMID:
31611880
2.

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M.

PLoS One. 2019 Sep 17;14(9):e0221994. doi: 10.1371/journal.pone.0221994. eCollection 2019.

3.

The trials and tribulations of CAR-T cell development for cancer and AIDS.

Hege K.

Nat Med. 2019 Aug;25(8):1183. doi: 10.1038/s41591-019-0538-8. No abstract available.

PMID:
31388173
4.

Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma. Reply.

Raje N, Hege K, Kochenderfer JN.

N Engl J Med. 2019 Jul 18;381(3):e6. doi: 10.1056/NEJMc1907520. No abstract available.

PMID:
31314982
5.

Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies.

Dylgjeri E, McNair C, Goodwin JF, Raymon HK, McCue PA, Shafi AA, Leiby BE, de Leeuw R, Kothari V, McCann JJ, Mandigo AC, Chand SN, Schiewer MJ, Brand LJ, Vasilevskaya I, Gordon N, Laufer TS, Gomella LG, Lallas CD, Trabulsi EJ, Feng FY, Filvaroff EH, Hege K, Rathkopf D, Knudsen KE.

Clin Cancer Res. 2019 Sep 15;25(18):5623-5637. doi: 10.1158/1078-0432.CCR-18-2207. Epub 2019 Jul 2.

PMID:
31266833
6.

DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.

Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY.

Clin Cancer Res. 2019 Sep 15;25(18):5608-5622. doi: 10.1158/1078-0432.CCR-18-2387. Epub 2019 Jul 2.

PMID:
31266829
7.

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN.

N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.

PMID:
31042825
8.

Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes.

Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM.

Am J Hematol. 2019 Jul;94(7):741-750. doi: 10.1002/ajh.25479. Epub 2019 Apr 29.

PMID:
30945320
9.

An Open-Label, Single-Arm, Efficacy Study of Tranexamic Acid in Adolescents with Heavy Menstrual Bleeding.

O'Brien SH, Saini S, Ziegler H, Christian-Rancy M, Ahuja S, Hege K, Savelli SL, Vesely SK.

J Pediatr Adolesc Gynecol. 2019 Jun;32(3):305-311. doi: 10.1016/j.jpag.2019.01.009. Epub 2019 Feb 5.

PMID:
30731217
10.

Analysis of Patient Characteristics and Risk Factors for Thrombosis After Surgery for Congenital Heart Disease.

Murphy LD, Benneyworth BD, Moser EAS, Hege KM, Valentine KM, Mastropietro CW.

Pediatr Crit Care Med. 2018 Dec;19(12):1146-1152. doi: 10.1097/PCC.0000000000001743.

PMID:
30234677
11.

A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies.

Rasco DW, Papadopoulos KP, Pourdehnad M, Gandhi AK, Hagner PR, Li Y, Wei X, Chopra R, Hege K, DiMartino J, Shih K.

Clin Cancer Res. 2019 Jan 1;25(1):90-98. doi: 10.1158/1078-0432.CCR-18-1203. Epub 2018 Sep 10.

PMID:
30201761
12.

Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.

Grace RF, Despotovic JM, Bennett CM, Bussel JB, Neier M, Neunert C, Crary SE, Pastore YD, Klaassen RJ, Rothman JA, Hege K, Breakey VR, Rose MJ, Shimano KA, Buchanan GR, Geddis A, Haley KM, Lorenzana A, Thompson A, Jeng M, Neufeld EJ, Brown T, Forbes PW, Lambert MP.

Am J Hematol. 2018 Jul;93(7):882-888. doi: 10.1002/ajh.25110. Epub 2018 May 6.

13.

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.

Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA.

J Immunother Cancer. 2017 Mar 21;5:22. doi: 10.1186/s40425-017-0222-9. eCollection 2017.

14.

Pulsed Radiation Therapy With Concurrent Cisplatin Results in Superior Tumor Growth Delay in a Head and Neck Squamous Cell Carcinoma Murine Model.

Meyer K, Krueger SA, Kane JL, Wilson TG, Hanna A, Dabjan M, Hege KM, Wilson GD, Grills I, Marples B.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):161-9. doi: 10.1016/j.ijrobp.2016.04.031. Epub 2016 May 7.

PMID:
27511853
15.

Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.

Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodríguez MS, Michot JM, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP.

Blood. 2016 Jul 28;128(4):574-83. doi: 10.1182/blood-2016-02-700328. Epub 2016 May 27.

PMID:
27235137
16.

Alemtuzumab, Fludarabine, Low-Dose TBI, and Double Umbilical Cord Transplant for Primary Graft Failure in a Patient with Recurrent HLH.

Hege K, Quigg T, Delgado D.

Pediatr Blood Cancer. 2016 Feb;63(2):361-3. doi: 10.1002/pbc.25782. Epub 2015 Oct 21.

PMID:
26488531
17.

A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN.

Cancer. 2015 Oct 1;121(19):3481-90. doi: 10.1002/cncr.29422. Epub 2015 Jul 15.

18.

Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.

Demosthenous C, Han JJ, Stenson MJ, Maurer MJ, Wellik LE, Link B, Hege K, Dogan A, Sotomayor E, Witzig T, Gupta M.

Oncotarget. 2015 Apr 20;6(11):9488-501.

20.

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, van den Eertwegh AJ, de Gruijl TD.

J Immunother Cancer. 2014 Sep 16;2:31. doi: 10.1186/s40425-014-0031-3. eCollection 2014.

21.

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12.

22.

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD.

Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10.

PMID:
22878899
23.

Oxygenation index predicts mortality in pediatric stem cell transplant recipients requiring mechanical ventilation.

Rowan CM, Hege KM, Speicher RH, Goodman M, Perkins SM, Slaven JE, Westenkirchner DF, Haut PR, Nitu ME.

Pediatr Transplant. 2012 Sep;16(6):645-50. doi: 10.1111/j.1399-3046.2012.01745.x. Epub 2012 Jun 18.

PMID:
22708708
24.

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.

Scholler J, Brady TL, Binder-Scholl G, Hwang WT, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH.

Sci Transl Med. 2012 May 2;4(132):132ra53. doi: 10.1126/scitranslmed.3003761.

25.

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR.

Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.

PMID:
22326922
26.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

27.

K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI.

Clin Cancer Res. 2010 Jan 1;16(1):338-47. doi: 10.1158/1078-0432.CCR-09-2046.

28.

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).

Borrello IM, Levitsky HI, Stock W, Sher D, Qin L, DeAngelo DJ, Alyea EP, Stone RM, Damon LE, Linker CA, Maslyar DJ, Hege KM.

Blood. 2009 Aug 27;114(9):1736-45. doi: 10.1182/blood-2009-02-205278. Epub 2009 Jun 25.

29.

Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.

Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ.

J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi: 10.1016/j.juro.2008.07.048. Epub 2008 Sep 17.

PMID:
18801509
30.

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

Laheru D, Lutz E, Burke J, Biedrzycki B, Solt S, Onners B, Tartakovsky I, Nemunaitis J, Le D, Sugar E, Hege K, Jaffee E.

Clin Cancer Res. 2008 Mar 1;14(5):1455-63. doi: 10.1158/1078-0432.CCR-07-0371.

31.

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer.

Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW.

Clin Cancer Res. 2007 Jul 1;13(13):3883-91.

32.

A clinical development paradigm for cancer vaccines and related biologics.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group.

J Immunother. 2007 Jan;30(1):1-15. Review.

PMID:
17198079
33.

GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.

Hege KM, Jooss K, Pardoll D.

Int Rev Immunol. 2006 Sep-Dec;25(5-6):321-52. Review.

PMID:
17169779
34.

Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.

Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, Clift SM, Hege KM, Ando DG, Piantadosi S, Mulligan R, Nelson WG.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3394-401.

35.

Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.

Nemunaitis J, Jahan T, Ross H, Sterman D, Richards D, Fox B, Jablons D, Aimi J, Lin A, Hege K.

Cancer Gene Ther. 2006 Jun;13(6):555-62.

PMID:
16410826
36.

Assessment of the fouling potential of wastewater treatment plant effluent using a modified capillary suction time measurement.

De Rudder J, Van Hege K, Verstraete W.

Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 2001;66(3a):145-8.

PMID:
15954575
37.

Biological membrane assisted carbon filtration for reuse of wastewater treatment plant effluent.

Van Hege K, Verstraete W.

Meded Rijksuniv Gent Fak Landbouwkd Toegep Biol Wet. 2001;66(4):113-7. No abstract available.

PMID:
15954274
38.

Recovery of a flawed hyperspectral imager calibration using optical modeling.

Johnson W, Hege K, O'Connell D, Dereniak E.

Opt Express. 2004 May 17;12(10):2251-7.

PMID:
19475061
39.

Electro-oxidative abatement of low-salinity reverse osmosis membrane concentrates.

Van Hege K, Verhaege M, Verstraete W.

Water Res. 2004 Mar;38(6):1550-8.

PMID:
15016532
40.
41.

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, Maples P, Hamilton S, Borellini F, Lin A, Morali S, Hege K.

J Natl Cancer Inst. 2004 Feb 18;96(4):326-31.

PMID:
14970281
42.

Lung cancer vaccines and gene therapy.

Hege KM, Carbone DP.

Lung Cancer. 2003 Aug;41 Suppl 1:S103-13. Review.

PMID:
12867069
43.

Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects.

Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, Macken C, Richman DD, Christopherson C, Borellini F, Lazar R, Hege KM.

AIDS. 2003 Jan 3;17(1):53-63.

PMID:
12478069
44.

Reclamation of treated domestic wastewater using biological membrane assisted carbon filtration (BioMAC).

Van Hege K, Dewettinck T, Claeys T, De Smedt G, Verstraete W.

Environ Technol. 2002 Sep;23(9):971-80.

PMID:
12361382
45.

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.

Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, Lazar R, Broad DF, Jalali S, Hege KM.

Mol Ther. 2002 Jun;5(6):788-97.

46.

Molecular fingerprinting of bacterial populations in groundwater and bottled mineral water.

Dewettinck T, Hulsbosch W, Van Hege K, Top EM, Verstraete W.

Appl Microbiol Biotechnol. 2001 Oct;57(3):412-8.

PMID:
11759695
47.

Development of a rapid pH-based biosensor to monitor and control the hygienic quality of reclaimed domestic wastewater.

Dewettinck T, Van Hege K, Verstraete W.

Appl Microbiol Biotechnol. 2001 Sep;56(5-6):809-15.

PMID:
11601634
48.

HACCP (Hazard Analysis and Critical Control Points) to guarantee safe water reuse and drinking water production--a case study.

Dewettinck T, Van Houtte E, Geenens D, Van Hege K, Verstraete W.

Water Sci Technol. 2001;43(12):31-8.

PMID:
11464766
49.

Pre-evaporative fenton remediation of treated municipal wastewater for reuse purposes.

Van Hege K, Dewettinck T, Verstraete W.

Environ Technol. 2001 May;22(5):523-32.

PMID:
11424729
50.

The electronic nose as a rapid sensor for volatile compounds in treated domestic wastewater.

Dewettinck T, Van Hege K, Verstraete W.

Water Res. 2001 Jul;35(10):2475-83.

PMID:
11394782

Supplemental Content

Support Center